Select your country

Websites worldwide

Select a country to go to the website of the respective STADA sales company.

Belarus (1)

Belgium (1)

Bosnia-Herzegovina (1)

Bulgaria (1)

Croatia (1)

Denmark (1)

Hungary (1)

Italy (1)

Montenegro (1)

Portugal (1)

Romania (1)

Saudi Arabia (1)

Serbia (1)

Slovenia (1)

Switzerland (1)

The Phillippines (1)

United Arab Emirates (1)

Entering into negotiations of a domination and profit and loss pooling agreement between STADA Arzneimittel AG and Nidda Healthcare Holding AG

  • 24/08/2017
  • Investor News
  • Press Release

Bad Vilbel, August 24, 2017 –

Nidda Healthcare Holding AG, the acquiring company of Bain Capital and Cinven, has today approached STADA Arzneimittel AG to discuss its intention to establish a domination and profit and loss transfer agreement pursuant to Section 291 ff AktG with Nidda Healthcare Holding AG or a related entity as the controlling company and STADA Arzneimittel AG as the controlled company. The Executive Board of STADA Arzneimittel AG has decided to enter into discussions with the Executive Board of Nidda Healthcare Holding AG on the conclusion of a domination and profit and loss transfer agreement. The minority shareholders of STADA Arzneimittel AG are to receive an offer by Nidda Healthcare Holding AG to purchase their shares against cash compensation and to pay compensation for the duration of the contract. The final form of the settlement scheme and the annual compensation payment in the contract will determine the companies in accordance with the legal requirements and on the basis of a business valuation.

About STADA Arzneimittel AG

STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. STADA consistently focuses on a multi-pillar strategy of generics and branded products (OTC) with an increasingly international market orientation. Worldwide, STADA is represented in more than 30 countries with more than 50 subsidiaries. Branded products such as Grippostad and Ladival are among the highest selling in their product category in Germany. In financial year 2016, STADA achieved adjusted Group sales of Euro 2,167.2 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 398 million and adjusted net income of Euro 177.3 million. As of December 31, 2016, STADA employed about 10.900 people worldwide.

Additional information for journalists:

STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail: